Apixaban

Generic Name: Apixaban

Brand Names: Eliquis, Apixaban Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₅N_₅O_₄

CAS Number: 503612-47-3

Unique Ingredient Identifier: 3Z9Y7UWC1J

Background: Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.

Indication: Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.

Associated Conditions: Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism

Associated Therapies: -

Clinical Trials

Eliquis Regulatory Post Marketing Surveillance

Completed

Conditions: NonValvular Atrial Fibrillation

Interventions: Drug: Apixaban

First Posted Date: 2013-06-25

Last Posted Date: 2017-10-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3335

Registration Number: NCT01885598

Locations: 🇰🇷
Local Institution, Seoul, Korea, Republic of

Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

Phase 4

Completed

Conditions: Anticoagulation

Interventions: Drug: Apixaban

First Posted Date: 2013-06-24

Last Posted Date: 2019-11-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 557

Registration Number: NCT01884337

Locations: 🇮🇳
Local Institution, Pune, India

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)

Phase 4

Completed

Conditions: Non-valvular Atrial Fibrillation

Interventions: Drug: Apixaban

First Posted Date: 2013-06-24

Last Posted Date: 2019-08-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1217

Registration Number: NCT01884350

Locations: 🇬🇧
Local Institution, Tauton, United Kingdom

AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients

Phase 3

Completed

Conditions: Deep Vein Thrombosis
Pulmonary Embolism

Interventions: Drug: Unfractionated Heparin (UFH)
Drug: Apixaban
Drug: Warfarin

First Posted Date: 2013-01-31

Last Posted Date: 2016-06-23

Lead Sponsor: Pfizer

Target Recruit Count: 80

Registration Number: NCT01780987

Locations: 🇯🇵
Toho University Sakura Medical Center, Sakura, Chiba, Japan
🇯🇵
Kokura Memorial Hospital, Kitakyusyu, Fukuoka, Japan
🇯🇵
National Cerebral and Cardiovascular Center Hospital, Suita-shi, Osaka, Japan

and more 17 locations

Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder

Phase 1

Completed

Conditions: Thromboembolism

Interventions: Drug: Apixaban

First Posted Date: 2012-10-16

Last Posted Date: 2021-03-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 49

Registration Number: NCT01707394

Locations: 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸
Childrens Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Children's Hopsital Of Pittsburgh Of UPMC, Pittsburgh, Pennsylvania, United States

and more 18 locations

Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events

Phase 3

Completed

Conditions: Hematoma

Interventions: Drug: Dabigatran
Drug: Rivaroxaban
Drug: Apixaban

First Posted Date: 2012-08-29

Last Posted Date: 2019-10-07

Lead Sponsor: Ottawa Heart Institute Research Corporation

Target Recruit Count: 663

Registration Number: NCT01675076

Locations: 🇨🇦
Victoria Cardiac Arrhythmia Trials Inc., Victoria, British Columbia, Canada
🇨🇦
University of Alberta-ECAT Group, Edmonton, Alberta, Canada
🇨🇦
Hamilton Health Sciences General Campus, Hamilton, Ontario, Canada

and more 12 locations

Food Effect Study For Apixaban Commercial Image Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Apixaban

First Posted Date: 2011-09-21

Last Posted Date: 2011-10-25

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT01437839

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis

Phase 1

Completed

Conditions: End Stage Renal Disease

Interventions: Drug: Apixaban

First Posted Date: 2011-04-22

Last Posted Date: 2016-10-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 18

Registration Number: NCT01340586

Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter

Phase 1

Terminated

Conditions: Venous Thromboembolism

Interventions: Drug: Apixaban

First Posted Date: 2010-09-06

Last Posted Date: 2017-04-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 13

Registration Number: NCT01195727

Locations: 🇺🇸
The Toledo Children'S Hospital, Toledo, Ohio, United States
🇺🇸
Penn State Hershey Children'S Hospital, Hershey, Pennsylvania, United States
🇺🇸
Children'S Hospital Of Orange County, Orange, California, United States

and more 2 locations

A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients

Phase 2

Terminated

Conditions: Acute Coronary Syndrome

Interventions: Drug: Apixaban
Other: Placebo

First Posted Date: 2009-02-27

Last Posted Date: 2013-08-29

Lead Sponsor: Pfizer

Target Recruit Count: 151

Registration Number: NCT00852397

Locations: 🇯🇵
Pfizer Investigational Site, Osaka, Japan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy